C-reactive protein and asymmetric dimethylarginine: Markers or mediators in cardiovascular disorders?

Current Pharmaceutical Design

Volumn 13, Issue 16, 2007, Pages 1619-1629

  Smith, Caroline L ^a  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

Asymmetric dimethylarginine; Atherosclerosis; C reactive protein; Cardiovascular risk factor; Dimethylarginine dimethylaminohydrolase; Nitric oxide; Protein arginine methyltransferase

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIMETHYLARGININASE; INFLIXIMAB; METFORMIN; METHYLTRANSFERASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RETINOIC ACID; ROSIGLITAZONE;

ANGINA PECTORIS; ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; GENETIC POLYMORPHISM; HEART INFARCTION; HEREDITY; HUMAN; HYPERGLYCEMIA; IN VIVO STUDY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SCREENING; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ARGININE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; NITRIC OXIDE; RISK ASSESSMENT; RISK FACTORS;

EID: 34250901665     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780831338     Document Type: Review

References (203)

1. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
2. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128.
3. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 2001; 358: 2113-2117.
4. Smith CL, Vallance P. Cardiovascular tests: Use & limits of biochemical markers - therapeutic measurements of ADMA involved in cardiovascular disorders. Curr Pharm Des 2005; 11: 2177-2185.
5. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982; 47: 239-243.
6. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-424.
7. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-466.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
9. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-860.
10. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
11. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
12. Pearson TA, Mensah GA, Alexander W, Anderson JL, Cannon RO, Criqui M, et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 2003; 107: 499-511.
13. Levinson SS, Miller JJ, Elin RJ. Poor predictive value of high-sensitivity C-reactive protein indicates need for reassessment. Clin Chem 2004; 50: 1733-1735.
14. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242-247.
15. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-658.
16. Wanby P, Teerlink T, Brudin L, Brattstrom L, Nilsson I, Palmqvist P, et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2006; 185: 271-7.
17. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158: 425-430.
18. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005; 25: 1414-1418.
19. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W, et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 2005; 19: 1175-1177.
20. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001; 37: 489-492.
21. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62: 339-345.
22. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-1459.
23. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): A potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002; 45: 1609-1616.
24. Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G, Wagner OF, et al. Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes. Diabetologia 2002; 45: 1372-1378.
25. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 2039-2044.
26. Maas R, Boger RH, Schwedhelm E, Casas JP, Lopez-Jaramillo P, Serrano N, et al. Plasma concentrations of asymmetric dimethylarginine (ADMA) in Colombian women with pre-eclampsia. JAMA 2004; 291: 823-824.
27. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop preeclampsia. Lancet 2003; 361: 1511-1517.
28. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62: 2425-2430.
29. Duan J, Murohara T, Ikeda H, Katoh A, Shintani S, Sasaki K, et al. Hypercholesterolemia inhibits angiogenesis in response to hindlimb ischemia: Nitric oxide-dependent mechanism. Circulation 2000; 102: III370-376.
30. Masuda H, Tsujii T, Okuno T, Kihara K, Goto M, Azuma H. Accumulated endogenous NOS inhibitors, decreased NOS activity, and impaired cavernosal relaxation with ischemia. Am J Physiol Regul Integr Comp Physiol 2002; 282: R1730-1738.
31. Boger RH, Bode-Boger SM, Brandes RP, Phivthong-ngam L, Bohme M, Nafe R, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: Comparison with lovastatin. Circulation 1997; 96: 1282-1290.
32. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847.
33. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intimamedia thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-496.
34. Loyaga-Rendon RY, Sakamoto S, Beppu M, Aso T, Ishizaka M, Takahashi R, et al. Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteries. Atherosclerosis 2005; 178: 231-239.
35. Selley ML. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 2003; 24: 903-907.
36. Abe T, Tohgi H, Murata T, Isobe C, Sato C. Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 2001; 312: 177-179.
37. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97-103.
38. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733-1740.
39. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
40. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: Evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 2005; 96: 61F-68F.
41. Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 1987; 111: 265-269.
42. Rowe IF, Walker LN, Bowyer DE, Soutar AK, Smith LC, Pepys MB. Immunohistochemical studies of C-reactive protein and apolipoprotein B in inflammatory and arterial lesions. J Pathol 1985; 145: 241-249.
43. van der Meer IM, de Maat MP, Bots ML, Breteler MM, Meijer J, Kiliaan AJ, et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: The Rotterdam Study. Arterioscler Thromb Vasc Biol 2002; 22: 838-842.
44. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104: 145-150.
45. Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Gallimore JR, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 2004; 109: 3022-3028.
46. Devlin J, Gough A, Huissoon A, Perkins P, Holder R, Reece R, et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 1997; 24: 9-13.
47. Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982; 9: 224-228.
48. Mallya RK, Hind CR, Berry H, Pepys MB. Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study. Arthritis Rheum 1985; 28: 383-387.
49. Mallya RK, Young BJ, Pepys MB, Hamblin TJ, Mace BE, Hamilton EB. Anti-keratin antibodies in rheumatoid arthritis: Frequency and correlation with other features of the disease. Clin Exp Immunol 1983; 51: 17-20.
50. Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997; 40: 723-727.
51. van Leeuwen MA, van Rijswijk MH, Sluiter WJ, van Riel PL, Kuper IH, van de Putte LB, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997; 24: 20-27.
52. Szalai AJ, Alarcon GS, Calvo-Alen J, Toloza SM, McCrory MA, Edberg JC, et al. Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: Association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) 2005; 44: 864-868.
53. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002; 3: 14-19.
54. Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13: 137-147.
55. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. [Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis]. J Cardiol 1999; 33: 105-106.
56. Zoccali C. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. Blood Purif 2002; 20: 469-472.
57. Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC. Elevated Larginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598-603.
58. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-3095.
59. Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287-2295.
60. Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao PS, Blaschke TF, et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 2000; 20: 1040-1046.
61. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005; 68: 2230-2236.
62. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 2003; 96: 793-807.
63. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.
64. de Beer FC, Soutar AK, Baltz ML, Trayner IM, Feinstein A, Pepys MB. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med 1982; 156: 230-242
65. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: Binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348-2354.
66. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-471.
67. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
68. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 647-655.
69. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2005; 102: 8309-8314.
70. Bae SW, Stuhlinger MC, Yoo HS, Yu KH, Park HK, Choi BY, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 2005; 95: 729-733
71. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005; 67: 2330-2337.
72. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-3378.
73. Alheid U, Frolich JC, Forstermann U. Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. Thromb Res 1987; 47: 561-571.
74. Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480-10484.
75. Gross SS, Levi R. Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Biol Chem 1992; 267: 25722-25729.
76. Vasquez-Vivar J, Hogg N, Martasek P, Karoui H, Pritchard KA Jr, Kalyanaraman B. Tetrahydrobiopterin-dependent inhibition of superoxide generation from neuronal nitric oxide synthase. J Biol Chem 1999; 274: 26736-26742.
77. Pou S, Keaton L, Surichamom W, Rosen GM. Mechanism of superoxide generation by neuronal nitric-oxide synthase. J Biol Chem 1999; 274: 9573-9580.
78. Gross SS, Stuehr DJ, Aisaka K, Jaffe EA, Levi R, Griffith OW. Macrophage and endothelial cell nitric oxide synthesis: Cell-type selective inhibition by NG-aminoarginine, NG-nitroarginine and NG-methylarginine. Biochem Biophys Res Commun 1990; 170: 96-103.
79. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101: 746-752.
80. Reporterer M, Corbin JL. N G,N G,-dimethylarginine in myosin during muscle development. Biochem Biophys Res Commun 1971; 43: 644-650.
81. Lou MF. Human muscular dystrophy: Elevation of urinary dimethylarginines. Science 1979; 203: 668-670.
82. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 Suppl 12: S60-62.
83. Olken NM, Rusche KM, Richards MK, Marletta MA. Inactivation of macrophage nitric oxide synthase activity by NG-methyl-L-arginine. Biochem Biophys Res Commun 1991; 177: 828-833.
84. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: Involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24: 1682-1688.
85. Testa A, Spoto B, Tripepi G, Mallamaci F, Malatino L, Fatuzzo P, et al. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. J Hypertens 2005; 23: 1825-1830.
86. Schmidt K, Klatt P, Mayer B. Uptake of nitric oxide synthase inhibitors by macrophage RAW 264.7 cells. Biochem J 1994; 301 (Pt 2): 313-316.
87. MacAllister RJ, Whitley GS, Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 1994; 45: 737-742.
88. Casellas P, Jeanteur P. Protein methylation in animal cells. I. Purification and properties of S-adenosyl-L-methionine: Protein (arginine) N-methyltransferase from Krebs II ascites cells. Biochim Biophys Acta 1978; 519: 243-254.
89. Miyake M, Kakimoto Y. Synthesis and degradation of methylated proteins of mouse organs: Correlation with protein synthesis and degradation. Metabolism 1976; 25: 885-896.
90. Small DH, Carnegie PR. In vivo methylation of an arginine in chicken myelin basic protein. J Neurochem 1982; 38: 184-190.
91. Branscombe TL, Frankel A, Lee JH, Cook JR, Yang Z, Pestka S, et al. PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J Biol Chem 2001; 276: 32971-32976.
92. Rho J, Choi S, Seong YR, Cho WK, Kim SH, Im DS. Prmt5, which forms distinct homo-oligomers, is a member of the protein-arginine methyltransferase family. J Biol Chem 2001; 276: 11393-11401.
93. Miranda TB, Miranda M, Frankel A, Clarke S. PRMT7 is a member of the protein arginine methyltransferase family with a distinct substrate specificity. J Biol Chem 2004; 279: 22902-22907.
94. Lee JH, Cook JR, Yang ZH, Mirochnitchenko O, Gunderson SI, Felix AM, et al. PRMT7, a new protein arginine methyltransferase that synthesizes symmetric dimethylarginine. J Biol Chem 2005; 280: 3656-3664.
95. Chen SL, Loffler KA, Chen D, Stallcup MR, Muscat GE. The coactivator-associated arginine methyltransferase is necessary for muscle differentiation: CARM1 coactivates myocyte enhancer factor-2. J Biol Chem 2002; 277: 4324-4333.
96. Frankel A, Clarke S. PRMT3 is a distinct member of the protein arginine N-methyltransferase family. Conferral of substrate specificity by a zinc-finger domain. J Biol Chem 2000; 275: 32974-32982.
97. Frankel A, Yadav N, Lee J, Branscombe TL, Clarke S, Bedford MT. The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity. J Biol Chem 2002; 277: 3537-3543.
98. Lee J, Sayegh J, Daniel J, Clarke S, Bedford MT. PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family. J Biol Chem 2005; 280: 32890-32896.
99. Tang J, Frankel A, Cook RJ, Kim S, Paik WK, Williams KR, Clarke S, Herschman HR. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 2000; 275: 7723-7730.
100. Tang J, Gary JD, Clarke S, Herschman HR. PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. J Biol Chem 1998; 273: 16935-16945.
101. Qi C, Chang J, Zhu Y, Yeldandi AV, Rao SM, Zhu YJ. Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha. J Biol Chem 2002; 277: 28624-28630.
102. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, Stallcup MR. Regulation of transcription by a protein methyltransferase. Science 1999; 284: 2174-2177.
103. Boisvert FM, Cote J, Boulanger MC, Cleroux P, Bachand F, Autexier C, et al. Symmetrical dimethylarginine methylation is required for the localization of SMN in Cajal bodies and pre-mRNA splicing. J Cell Biol 2002; 159: 957-969.
104. Cook JR, Lee J, Yang ZH, Krause CD, Herth N, Hoffmann R, et al. FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues. Biochem Biophys Res Comm 2006; 342: 472-81.
105. McDermott JR. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 1976; 154: 179-184.
106. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989; 264: 10205-10209.
107. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987; 148: 671-677.
108. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-9.
109. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343(Pt 1): 209-214.
110. Tran CT, Fox MF, Vallance P, Leiper JM. Chromosomal localization, gene structure, and expression pattern of DDAH1: Comparison with DDAH2 and implications for evolutionary origins. Genomics 2000; 68: 101-105.
111. Arrigoni FI, Vallance P, Haworth SG, Leiper JM. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 2003; 107: 1195-1201.
112. Tillett WSF, T. Jr. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930; 52: 561-585.
113. Whitehead AS, Bruns GA, Markham AF, Colten HR, Woods DE. Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. Science 1983; 221: 69-71.
114. Floyd-Smith G, Whitehead AS, Colten HR, Francke U. The human Creactive protein gene (CRP) and serum amyloid P component gene (APCS) are located on the proximal long arm of chromosome 1. Immunogenetics 1986; 24: 171-176.
115. Volanakis JE, Kaplan MH. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med 1971; 136: 612-614.
116. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure Fold Des 1999; 7: 169-177.
117. Tebo JM, Mortensen RF. Characterization and isolation of a C-reactive protein receptor from the human monocytic cell line U-937. J Immunol 1990; 144: 231-238.
118. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med 1999; 190: 585-590.
119. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974; 112: 2135-2147.
120. Volanakis JE, Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: Requirement for human C1q. J Immunol 1974; 113: 9-17.
121. Claus DR, Siegel J, Petras K, Skor D, Osmand AP, Gewurz H. Complement activation by interaction of polyanions and polycations. III. Complement activation by interaction of multiple polyanious and polycations is the presence of C-reactive protein. J Immunol 1977; 118: 83-87.
122. Siegel J, Rent R, Gewurz H. Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med 1974; 140: 631-647.
123. Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 2001; 38: 189-197.
124. Robey FA, Jones KD, Tanaka T, Liu TY. Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J Biol Chem 1984; 259: 7311-7316.
125. Fiedel BA, Gewurz H. Effects of C-reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions. J Immunol 1976; 116: 1289-1294.
126. Shrive AK, Cheetham GM, Holden D, Myles DA, Turnell WG, Volanakis JE, et al. Three dimensional structure of human C-reactive protein. Nat Struct Biol 1996; 3: 346-354.
127. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004; 279: 48487-48490.
128. Motie M, Brockmeier S, Potempa LA. Binding of model soluble immune complexes to modified C-reactive protein. J Immunol 1996; 156: 4435-4441.
129. Khreiss T, Jozsef L, Potempa LA, Filep JG. Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 2005; 97: 690-697.
130. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534.
131. Khreiss T, Jozsef L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 2004; 109: 2016-2022.
132. Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112: 1016-1023.
133. Pepys MB, Baltz M, Gomer K, Davies AJ, Doenhoff M. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 1979; 278: 259-261.
134. Robey FA, Liu TY. Limulin: A C-reactive protein from Limulus polyphemus. J Biol Chem 1981; 256: 969-975.
135. Pepys MB. CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 2005; 25: 1091-1094.
136. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-1441.
137. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919.
138. Clapp BR, Hirschfield GM, Storry C, Gallimore JR, Stidwill RP, Singer M, et al. Inflammation and endothelial function: Direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005; 111: 1530-1536.
139. Ikeda U, Maeda Y, Yamamoto K, Shimada K. C-Reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovasc Res 2002; 56: 86-92.
140. van den Berg CW, Taylor KE, Lang D. C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol 2004; 24: E168-171.
141. Swafford AN, Jr., Bratz IN, Knudson JD, Rogers PA, Timmerman JM, Tune JD, Dick GM. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am J Physiol Heart Circ Physiol 2005; 288: H1786-1795.
142. Lafuente N, Azcutia V, Matesanz N, Cercas E, Rodriguez-Manas L, Sanchez-Ferrer CF, et al. Evidence for sodium azide as an artifact mediating the modulation of inducible nitric oxide synthase by C-reactive protein. J Cardiovasc Pharmacol 2005; 45: 193-196.
143. Taylor KE, Giddings JC, van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005; 25: 1225-1230
144. Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: Implications of contaminating presence of sodium azide in commercial preparation. Circ Res 2005; 97: 135-143.
145. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, et al. Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself. Circ Res 2005.
146. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-2575.
147. Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M, et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: Role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 2005; 16: 892-898.
148. Zsuga J, Gesztelyi R, Torok J, Keki S, Bereczki D. Asymmetric dimethylarginine: A molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition. Med Hypotheses 2005; 65: 1091-1098.
149. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-992.
150. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, Reaven GM, Tsao PS. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51: 843-846.
151. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous
152. Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005; 28: 255-262.
153. Jones LC, Tran CT, Leiper JM, Hingorani AD, Vallance P. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 2003; 310: 836-843.
154. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: Role of dimethylarginine dimethylaminohydrolase. Circ Res 2003; 92: 226-233.
155. Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 2003; 108: 1575-1580.
156. Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: A role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 2002; 90: 764-769.
157. Laussmann T, Janosi RA, Fingas CD, Schlieper GR, Schlack W, Schrader J, et al. Myocardial proteome analysis reveals reduced NOS inhibition and enhanced glycolytic capacity in areas of low local blood flow. FASEB J 2002; 16: 628-630.
158. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003; 42: 985-990.
159. Rizzo V, McIntosh DP, Oh P, Schnitzer JE. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J Biol Chem 1998; 273: 34724-34729.
160. Teerlink T, Neele SJ, de Jong S, Netelenbos JC, Stehouwer CD. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) 2003; 105: 67-71.
161. Smith CL, Birdsey GM, Anthony S, Arrigoni FI, Leiper JM, Vallance P. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 2003; 308: 984-989.
162. Kostourou V, Robinson SP, Cartwright JE, Whitley GS. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 2002; 87: 673-680.
163. Kostourou V, Troy H, Murray JF, Cullis ER, Whitley GS, Griffiths JR, et al. Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: An insight into the relationship of hypoxia and angiogenesis in vivo. Neoplasia 2004; 6: 401-411.
164. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence. Circulation 2003; 108: 3042-3047.
165. Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B, et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005; 111: 1431-1438.
166. Majello B, Arcone R, Toniatti C, Ciliberto G. Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter. Embo J 1990; 9: 457-465.
167. Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G. Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO J 1990; 9: 4467-4475.
168. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 1989; 8: 3773-3779.
169. Zhang D, Sun M, Samols D, Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 1996; 271: 9503-9509.
170. Voleti B, Agrawal A. Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kappaB on the proximal promoter. J Immunol 2005; 175: 3386-3390.
171. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.
172. Wang TJ, Larson MG, Levy D, Benjamin EJ, Kupka MJ, Manning WJ, et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: The Framingham Heart Study. Circulation 2002; 106: 1189-1191.
173. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II2-10.
174. Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: A model of vascular inflammation. Circulation 2004; 109: 1718-1723.
175. Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N, et al. Complement activation in angiotensin II-induced organ damage. Circ Res 2005; 97: 716-724.
176. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004; 42: 1377-1383.
177. Valtonen P, Karppi J, Nyyssonen K, Valkonen VP, Halonen T, Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2005.
178. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002; 303: 131-137.
179. Martens-Lobenhoffer J, Bode-Boger SM. Measurement of asymmetric dimethylarginine (ADMA) in human plasma: From liquid chromatography estimation to liquid chromatography-mass spectrometry quantification. Eur J Clin Pharmacol 2005: 1-8.
180. Siboo R, Kulisek E. A fluorescent immunoassay for the quantification of C-reactive protein. J Immunol Methods 1978; 23: 59-67.
181. De Beer FC, Shine B, Pepys MB. Radiometric ligand binding assay for C-reactive protein. Complexed C-reactive protein is not detectable in acute phase serum. Clin Exp Immunol 1982; 50: 231-237.
182. Akbar F, Heinonen S, Pirskanen M, Uimari P, Tuomainen TP, Salonen JT. Haplotypic association of DDAH1 with susceptibility to pre-eclampsia. Mol Hum Reprod 2005; 11: 73-77.
183. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, et al. Human CRP gene polymorphism influences CRP levels: Implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003; 23: 2063-2069.
184. D'Aiuto F, Casas JP, Shah T, Humphries SE, Hingorani AD, Tonetti MS. C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis 2005; 179: 413-417.
185. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005; 77: 64-77
186. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002; 162: 217-219.
187. D'Aiuto F, Parkar M, Brett PM, Ready D, Tonetti MS. Gene polymorphisms in pro-inflammatory cytokines are associated with systemic inflammation in patients with severe periodontal infections. Cytokine 2004; 28: 29-34.
188. Eklund C, Lehtimaki T, Hurme M. Epistatic effect of C-reactive protein (CRP) single nucleotide polymorphism (SNP) +1059 and interleukin-1B SNP +3954 on CRP concentration in healthy male blood donors. Int J Immunogenet 2005; 32: 229-232.
189. Araujo F, Pereira AC, Mota GF, Latorre Mdo R, Krieger JE, Mansur AJ. The influence of tumor necrosis factor -308 and C-reactive protein G1059C gene variants on serum concentration of C-reactive protein: Evidence for an age-dependent association. Clin Chim Acta 2004; 349: 129-134.
190. Kolek MJ, Carlquist JF, Muhlestein JB, Whiting BM, Horne BD, Bair TL, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004; 148: 1034-1040.
191. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon Gene Expression: An Insight into the Pathophysiological Significance of Raised Plasma ADMA. PLoS Med 2005; 2: E264.
192. Thum T, Tsikas D, Stein S, Schultheiss M, Eigenthaler M, Anker SD, Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005; 46: 1693-1701.
193. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 1999; 20: 954-959.
194. Cross JM, Donald AE, Kharbanda R, Deanfield JE, Woolfson RG, MacAllister RJ. Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int 2001; 60: 2318-2323.
195. Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 1998; 53: 1068-1077.
196. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-1540.
197. Rossiter S, Smith CL, Malaki M, Nandi M, Gill H, Leiper JM, et al. Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase. J Med Chem 2005; 48: 4670-4678.
198. Stone EM, Schaller TH, Bianchi H, Person MD, Fast W. Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: Dimethylargininase and peptidylarginine deiminase. Biochemistry 2005; 44: 13744-13752.
199. Knipp M, Braun O, Vasak M. Searching for DDAH inhibitors: S-nitroso-L-homocysteine is a chemical lead. J Am Chem Soc 2005; 127: 2372-2373.
200. Leiper J, Nandi M, Torendel B, Murray-Rust J, Malaki M, O'Hara B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007; 13: 198-203.
201. Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr Pharm Des 2006; 12(13): 1623-35.
202. Rodriguez-Feo JA, Sluijter JP, de Kleijn DP, Pasterkamp G. Modulation of collagen turnover in cardiovascular disease. Curr Pharm Des 2005; 11(19): 2501-14.
203. Smith CL, Vallance P. Cardiovascular tests: Use & limits of biochemical markers - therapeutic measurements of ADMA involved in cardiovascular disorders. Curr Pharm Des 2005; 11(17): 2177-85.